Channel Therapeutics Inc. - PTHS Enterprise Value-to-Sales Ratio

Public company logo of channeltherapeutics.com (PTHS)

The market capitalization-to-revenue chart for Channel Therapeutics (PTHS) demonstrates a period of portfolio adaptation to new goals set by management. Due to costly clinical trials, earnings remain negative and FCF is volatile. Meanwhile, a team of elite neurobiologists is receiving generous resources for drug discovery. Consequently, 1514.33 becomes the new value of the metric, capturing the current market assessment of the business's efficiency.

Channel Therapeutics (PTHS): EV/Sales Multiple from 11/23/2025 to 11/20/2026

Channel Therapeutics Inc. - analytical breakdowns and key metrics (PTHS)

Initial company analysis:channeltherapeutics.com, PTHS
Product sample of Channel Therapeutics Corp

For an investor assessing the issuer's financial stability, this indicator reflects the total business value (Enterprise Value) minus debt obligations per unit of revenue. The EV/Sales trajectory demonstrates the operational efficiency of Channel Therapeutics (PTHS), where strict adherence to bioethical standards and ESG principles in the development of neurological drugs directly impacts the company's market capitalization and investment attractiveness.